title: Evaluation of ethanolamine oleate sclerotherapy on the submandibular glands of canines as a potential therapy for sialorrhea.
abstract: BACKGROUND
  Sialorrhea can have major negative effects on the physical and social well-being. Sclerotherapy may be useful in patients with sialorrhea by decreasing the amount of saliva production. The aim of this study was to test the effect of ethanolamine oleate (EO) in an experimental model as a preliminary step for its application in humans.
  
  
  METHODS
  Histopathological and morphometric analysis of submandibular glands from thirteen dogs was preformed. A total of 25 glands were injected with 1ml of 2.5% EO (n=5), 1ml of 5% EO (n=5), 5ml of 2.5% EO (n=5) and 5ml of 5% EO (n=5). Five glands were used as control.
  
  
  RESULTS
  EO significantly induced a dose dependent scaring of the gland ending in lobular transformation (salivary gland cirrhosis). Morphometric measurements showed that 1ml of 2.5% or 5% EO significantly induced fibrosis compared to normal glands (p=0.014 and 0.021, respectively). Fibrosis significantly increased and was more apparent when a dose of 5ml of 2.5% EO or 5% EO were injected [by semi-quantitative evaluation (p=0.016 and 0.002, respectively) and morphometric measurements (p=0.016 and 0.008, respectively)]. This scarring effect was significantly associated with reduction of area of acinar cells when a dose of 1ml-5%, 5ml-2.5% or 5ml-5% EO were applied (p=0.03. 0.012 and 0.004, respectively). Moreover, ductal injury was only significant when a dose of 5ml of 5% EO was used (p=0.034). This dose and concentration (i.e. 5ml-5% EO) had a significant synergetic effect [p=0.0119].
  
  
  CONCLUSIONS
  In this model, treatment with EO proved to permanently reduce the acinar area through induction of progressive, irreversible and dose dependant scarring (medical sialoadenectomy).
authors.affiliation: ENT Department, Faculty of Medicine, Misr University for Science and Technology, 6th of October city, Giza, Egypt.
authors.forename: F
authors.initials: F
authors.lastname: Abbas
authors.forename: R
authors.initials: R
authors.lastname: Farid
authors.forename: I
authors.initials: I
authors.lastname: Nada
authors.forename: M
authors.initials: M
authors.lastname: El-Sharnouby
mesh_terms: D000818:Animals; D004285:Dogs; D009829:Oleic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D012597:Sclerosing Solutions / Q000494:pharmacology*; D015911:Sclerotherapy / Q000009:adverse effects / Q000379:methods*; D012798:Sialorrhea / Q000188:drug therapy* / Q000473:pathology; D013363:Submandibular Gland / Q000473:pathology*
chemical_list: D009829:Oleic Acids; D012597:Sclerosing Solutions; C033343:ethanolamine oleate